A Review of the Literature on the Relationships Between Genetic Polymorphisms and Chemotherapy-induced Nausea and Vomiting

Overview

Journal Crit Rev Oncol Hematol

Specialty Hematology

Date 2017 Dec 28

PMID 29279099

Citations 14

Authors

Komal P Singh

Anand A Dhruva

Elena Flowers

Kord M Kober

Christine Miaskowski

Affiliations

Soon will be listed here.

Abstract

Despite current advances in antiemetic treatments, between 30% to and 60% of oncology patients experience chemotherapy-induced nausea (CIN) and 13% to 33% report chemotherapy-induced vomiting (CIV). Inter-individual differences are observed in the occurrence and severity of chemotherapy-induced nausea and vomiting (CINV). This review summarizes and critiques studies on associations between occurrence and severity of CINV and polymorphisms in serotonin receptor, drug metabolism, and drug transport pathway genes. Sixteen studies evaluated the associations between the occurrence and/or severity of CINV and single nucleotide polymorphisms (SNPs). Across these studies, three SNPs in 5-hydroxytryptamine receptor (5-HT3R) genes, two alleles of the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, and three SNPs in ATP binding cassette subfamily B member 1 (ABCB1) gene were associated with the occurrence and severity of CINV. Given the limited number of polymorphisms evaluated, additional research is warranted to identify new mechanisms to develop more targeted therapies.

Citing Articles

Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy.

Marangoni-Iglecias L, Rojo-Tolosa S, Marquez-Pete N, Cura Y, Moreno-Toro N, Membrive-Jimenez C Int J Mol Sci. 2024; 25(16).

PMID: 39201483 PMC: 11354794. DOI: 10.3390/ijms25168797.

Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients.

Ghorbani M, Namazi S, Dehghani M, Razi F, Khalvati B, Dehshahri A Cancer Chemother Pharmacol. 2024; 94(2):237-250.

PMID: 38678150 DOI: 10.1007/s00280-024-04661-9.

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials.

Yeo W, Ngai N, Yip C, Mo F, Yeo V, Ko J Cancer Manag Res. 2024; 16:283-297.

PMID: 38617187 PMC: 11012748. DOI: 10.2147/CMAR.S447546.

CYP2D6 isoenzyme and ABCB1 gene polymorphisms associated with postoperative nausea and vomiting in women undergoing laparoscopic cholecystectomy: a randomized trial.

Henrique Silva Ribeiro A, Braga E, Ferreira N, Olej B, Vercosa N, Antunes L Braz J Anesthesiol. 2023; 74(3):744423.

PMID: 36841429 PMC: 11148501. DOI: 10.1016/j.bjane.2023.02.002.

Metagenomics and chemotherapy-induced nausea: A roadmap for future research.

Crowder S, Hoogland A, Welniak T, LaFranchise E, Carpenter K, Li D Cancer. 2021; 128(3):461-470.

PMID: 34643945 PMC: 8776572. DOI: 10.1002/cncr.33892.

References

Janelsins M, Tejani M, Kamen C, Peoples A, Mustian K, Morrow G . Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother. 2013; 14(6):757-66. PMC: 3938333. DOI: 10.1517/14656566.2013.776541. View

Morisaki K, Robey R, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K . Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol. 2005; 56(2):161-72. DOI: 10.1007/s00280-004-0931-x. View

Vivona D, Lima L, Rodrigues A, Bueno C, Alcantara G, Barros L . ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett. 2014; 7(4):1313-1319. PMC: 3961201. DOI: 10.3892/ol.2014.1857. View

Rao K, Faso A . Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits. 2014; 5(4):232-40. PMC: 4046471. View

Ward M, Kotasek D, McKinnon R . Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics. 2008; 9(8):1027-33. DOI: 10.2217/14622416.9.8.1027. View

Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa S, Isambert N . Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2013; 47(5):839-848.e4. DOI: 10.1016/j.jpainsymman.2013.06.012. View

Babaoglu M, Bayar B, Sukru Aynacioglu A, Kerb R, Abali H, Celik I . Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther. 2005; 78(6):619-26. DOI: 10.1016/j.clpt.2005.08.015. View

Perwitasari D, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier J . Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm. 2011; 33(1):33-43. PMC: 3042115. DOI: 10.1007/s11096-010-9454-1. View

Jordan K, Gralla R, Jahn F, Molassiotis A . International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2013; 722:197-202. DOI: 10.1016/j.ejphar.2013.09.073. View

10.

Grunberg S, Warr D, Gralla R, Rapoport B, Hesketh P, Jordan K . Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer. 2010; 19 Suppl 1:S43-7. DOI: 10.1007/s00520-010-1003-x. View

11.

Sprowl J, Ness R, Sparreboom A . Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet. 2012; 28(1):19-27. PMC: 3705946. DOI: 10.2133/dmpk.dmpk-12-rv-073. View

12.

Hofman M, Morrow G, Roscoe J, Hickok J, Mustian K, Moore D . Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center--Community Clinical Oncology Program study of 938 patients from community practices. Cancer. 2004; 101(4):851-7. DOI: 10.1002/cncr.20423. View

13.

Pud D, Har-Zahav G, Laitman Y, Rubinek T, Yeheskel A, Ben-Ami S . Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer. Breast Cancer Res Treat. 2014; 144(1):123-31. DOI: 10.1007/s10549-014-2832-y. View

14.

Bloechl-Daum B, Deuson R, Mavros P, Hansen M, Herrstedt J . Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006; 24(27):4472-8. DOI: 10.1200/JCO.2006.05.6382. View

15.

Cohen L, de Moor C, Eisenberg P, Ming E, Hu H . Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2006; 15(5):497-503. DOI: 10.1007/s00520-006-0173-z. View

16.

Basch E, Prestrud A, Hesketh P, Kris M, Feyer P, Somerfield M . Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29(31):4189-98. PMC: 4876353. DOI: 10.1200/JCO.2010.34.4614. View

17.

Perwitasari D, Wessels J, van der Straaten R, Baak-Pablo R, Mustofa M, Hakimi M . Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol. 2011; 41(10):1168-76. DOI: 10.1093/jjco/hyr117. View

18.

Hesketh P, Aapro M, Street J, Carides A . Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2009; 18(9):1171-7. DOI: 10.1007/s00520-009-0737-9. View

19.

Hammer C, Fasching P, Loehberg C, Rauh C, Ekici A, Jud S . Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics. 2010; 11(7):943-50. DOI: 10.2217/pgs.10.67. View

20.

Sugino S, Janicki P . Pharmacogenetics of chemotherapy-induced nausea and vomiting. Pharmacogenomics. 2015; 16(2):149-60. DOI: 10.2217/pgs.14.168. View